Department of Emergency, Xi'an Children's Hospital (Xi'an Jiaotong University Affiliated Children's Hospital), China.
Department of Emergency, Xi'an Children's Hospital (Xi'an Jiaotong University Affiliated Children's Hospital), China.
Eur J Paediatr Neurol. 2024 Sep;52:67-75. doi: 10.1016/j.ejpn.2024.07.009. Epub 2024 Jul 19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes acute necrotizing encephalopathy (ANE), which has a high mortality rate and severe sequelae. This study aimed to identify ANE early and evaluate the usefulness of tocilizumab in ANE treatment.
We retrospectively included eight paeefediatric ANE cases infected with SARS-CoV-2 at Xi'an Children's Hospital, China, from December 1, 2022 to May 1, 2023. A literature search was performed using the PUBMED, SPRING, SCOPUS, and EMBASE databases. This study included eleven patients. Clinical characteristics, laboratory test results, imaging features, and treatment options were analysed.
Eight of the 19 cases (42 %) died, one (5 %) recovered, and nine (47 %) improved with residual neurological dysfunction. Eighteen patients presented with fever, with 56 % having ≥40 °C. Twelve patients (63 %) presented with dysfunction consciousness. Eight (42 %) patients experienced frequent convulsions. All eight patients in our hospital had elevated procalcitonin levels (mean: 21.32 ng/mL, range: 0.10-89.40 ng/mL). Alanine aminotransferase levels were elevated (mean: 632.81 U/L, range: 13.00-2251.00 U/L) in six patients. Seven patients showed elevated uric acid levels(mean: 396.50 μmol/L, range: 157.00-660.00 μmol/L). Brain imaging indicated that all the patients had symmetrical injuries to the bilateral thalami, accompanied by symmetrical injuries in the cerebrum, cerebellum, basal ganglia, and brain stem. Compared with the classical treatment (n = 9), the combination with tocilizumab (n = 6) showed a statistically difference in mortality (p = 0.028 < 0.05).
The typical clinical manifestations of ANE in children with SARS-CoV-2 infection are acute onset with high fever, frequent convulsions and rapidly worsening disturbance of consciousness. Tocilizumab treatment could reduces mortality in ANE.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)可引起急性坏死性脑病(ANE),其死亡率高,且有严重的后遗症。本研究旨在早期识别 ANE,并评估托珠单抗在 ANE 治疗中的作用。
我们回顾性纳入了 2022 年 12 月 1 日至 2023 年 5 月 1 日期间在中国西安儿童医院因 SARS-CoV-2 感染的 8 例儿科 ANE 患者。使用 PUBMED、SPRING、SCOPUS 和 EMBASE 数据库进行文献检索。本研究共纳入 11 例患者。分析了临床特征、实验室检查结果、影像学特征和治疗选择。
19 例患者中,8 例(42%)死亡,1 例(5%)痊愈,9 例(47%)好转但遗留神经功能障碍。18 例患者发热,56%的患者体温≥40℃。12 例患者意识障碍。8 例(42%)患者频繁抽搐。我们医院的 8 例患者降钙素原水平升高(平均:21.32ng/ml,范围:0.10-89.40ng/ml)。6 例患者丙氨酸氨基转移酶水平升高(平均:632.81U/L,范围:13.00-2251.00U/L)。7 例患者血尿酸水平升高(平均:396.50μmol/L,范围:157.00-660.00μmol/L)。脑影像学检查提示所有患者双侧丘脑对称性损伤,同时伴有大脑、小脑、基底节和脑干对称性损伤。与经典治疗(n=9)相比,联合托珠单抗(n=6)的死亡率有统计学差异(p=0.028<0.05)。
SARS-CoV-2 感染儿童 ANE 的典型临床表现为急性起病,高热,频繁抽搐,意识障碍迅速恶化。托珠单抗治疗可降低 ANE 的死亡率。